HUTCHMED Reports 2024 Full Year Results and Provides Business Updates
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”, the “Company” or “we”) ...
HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma
TAZVERIK ® is a registered trademark of Epizyme Inc., an Ipsen company.
ETF Daily News8d
Amundi Has $2.59 Million Position in HUTCHMED (China) Limited (NASDAQ:HCM)
Amundi cut its holdings in shares of HUTCHMED (China) Limited (NASDAQ:HCM – Free Report) by 2.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange ...
Investing11d
HUTCHMED executive’s long-term incentive plan vests
HONG KONG, SHANGHAI, FLORHAM PARK, NJ - HUTCHMED (China) Limited (Nasdaq/AIM: HCM; HKEX: 13) disclosed that its Executive Director, Chief Executive Officer, and Chief Scientific Officer ...
Yahoo Finance15d
HUTCHMED (China) (LON:HCM) shareholders have earned a 3.7% CAGR over the last three years
But if you choose individual stocks with prowess, you can make superior returns. Just take a look at HUTCHMED (China) Limited (LON:HCM), which is up 12%, over three years, soundly beating the ...
ETF Daily News18d
HUTCHMED (LON:HCM) Share Price Crosses Below 200 Day Moving Average – Should You Sell?
HUTCHMED shares last traded at GBX 248 ($3.20), with a volume of 20,179 shares traded. HUTCHMED Trading Up 4.4 % The stock has a market cap of £2.81 billion, a P/E ratio of -66.10 and a beta of 0.76.
Mena FN20d
HUTCHMED Announces Appointment Of Independent Non-Executive Director And Member Of Board Committee
(MENAFN- GlobeNewsWire - Nasdaq) HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 05, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the ...
Yahoo Finance15d
HUTCHMED (China) (LON:HCM) shareholders have earned a 3.7% CAGR over the last three years
But if you choose individual stocks with prowess, you can make superior returns. Just take a look at HUTCHMED (China) Limited (LON:HCM), which is up 12%, over three years, soundly beating the market ...
Yahoo Finance18d
Hutchmed concludes enrolment in Phase II trial of fanregratinib for IHCC
Hutchmed has concluded enrolment of its multi-centre Phase II trial of fanregratinib (HMPL-453), a treatment for intrahepatic cholangiocarcinoma (IHCC) individuals with fibroblast growth factor ...
Nasdaq19d
HUTCHMED Completes Enrollment in Phase II Trial of Fanregratinib for Intrahepatic Cholangiocarcinoma Patients with FGFR2 Fusion/Rearrangement
HUTCHMED has announced the completion of patient enrollment in a Phase II trial for fanregratinib (HMPL-453), aimed at treating intrahepatic cholangiocarcinoma (IHCC) patients with FGFR2 fusion ...
Investing11d
HUTCHMED executive’s long-term incentive plan vests
HONG KONG, SHANGHAI, FLORHAM PARK, NJ - HUTCHMED (China) Limited (Nasdaq/AIM: HCM; HKEX: 13) disclosed that its Executive Director, Chief Executive Officer, and Chief Scientific Officer, Dr. Weiguo Su ...
Investing11d
Hutchmed launches new long-term incentive plan
HONG KONG - Hutchmed (China) Limited (Nasdaq/AIM:HCM; HKEX:13), a biopharmaceutical company focused on cancer and immunological diseases, announced the adoption of its 2025 Long Term Incentive ...